Pharma BD Deal Intelligence
Eli Lilly is paying up to $1.55B for Vaccine Company's Phase-1-ready, five-antigen Epstein-Barr Virus vaccine on its In Vivo Nanoparticle platform, the largest of three simultaneous vaccine buyouts Lilly announced May 26 — a preclinical-stage wager on unproven prevention economics.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly dives into vaccine research with 3 biotech buyouts including Vaccine Company at up to $1.55 billion for an Epstein-Barr virus program. The acquisitions…
LLY Acquires Vaccine Company Focused on Innovative Nanoparticle Technology. Vaccine Company is advancing a preclinical pipeline focused on various viral…
Eli Lilly to buy three small vaccine developers. The deal for Vaccine Company at up to $1.55 billion targets Epstein-Barr virus, which is linked to multiple…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly agreed to acquire Vaccine Company, Inc. for up to $1.55B (upfront plus milestones). Vaccine Company develops proprietary In Vivo Nanoparticle (IVN) technology that mimics virus-like-particle immunogenicity without traditional VLP manufacturing burden; lead Phase-1-ready candidate is a five-antigen Epstein-Barr Virus vaccine, with broader pipeline across viral pathogens. Part of Lilly's three-deal infectious disease push announced May 26.
125K US cases/yr · $5.0B Analyst peak EBV vaccine TAM estimates (Leerink/JPM) covering adolescent + at-risk adult populations
EBV is one of the most common human viruses with US seroprevalence reaching ~83% by age 18-19. Acute infection causes infectious mononucleosis; lifelong latency is causally implicated in multiple sclerosis (32-fold MS risk increase post-EBV seroconversion per landmark 2022 Science study) and several malignancies (Hodgkin lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, post-transplant lymphoproliferative disease). No EBV vaccine is currently licensed.
EBV vaccine race includes Moderna (mRNA-1189 in Phase 1), Modex (gp350 ferritin nanoparticle), NIH Vaccine Research Center programs and academic consortia. No candidate is yet approved. Vaccine Company's IVN platform displays five EBV antigens simultaneously to mimic VLP immunogenicity without VLP manufacturing burden, theoretically broadening neutralizing breadth versus single-antigen approaches. Lilly's acquisition gives a capital-constrained Phase 1-ready asset commercial muscle and access to MS franchise economics if EBV-MS causal link translates to disease prevention.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Vaccine Company, Inc. (this deal) | 2026 | $1.6B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Neurology deals